24
Participants
Start Date
August 20, 2021
Primary Completion Date
May 15, 2022
Study Completion Date
December 15, 2022
Dasiglucagon
Abdominal s.c. self-administration 120 µg of dasiglucagon when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
HyoPen
multi-dose reusable pen injector
Placebo
Abdominal s.c. self-administration with placebo when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, Hellerup
Collaborators (1)
Zealand Pharma
INDUSTRY
Filip Krag Knop
OTHER